jetcityimage/iStock Editorial via Getty Images
Walgreens Boots (NASDAQ:WBA) is scheduled to announce Q2 earnings results on Tuesday, March 28th, before market open.
The consensus EPS Estimate is $1.11 (-30.2% Y/Y) and the consensus Revenue Estimate is $33.56B (-0.6% Y/Y).
Over the last 2 years, WBA has beaten EPS estimates 100% of the time and has beaten revenue estimates 88% of the time.
Over the last 3 months, EPS estimates have seen 1 upward revision and 12 downward. Revenue estimates have seen 9 upward revisions and 0 downward.
The company on Jan. 5 reported Q1 Non-GAAP EPS of $1.16, beating estimates by 2 cents. Revenue of $33.38B was ahead of consensus by $340M.
WBA has a Quant rating of HOLD, with a 3.22 rating score.
WBA has an industry ranking of 74 out of 191 in the consumer staples sector, but is the top ranking stock in the drug retail industry, as per SA’s Quant ranking.
Wall Street analysts rate the WBA stock HOLD, while Seeking Alpha authors rate it BUY.
Recent Analysis: “Where WBA’s stock heads in the next several years will largely depend on how well its Healthcare segment performs. While I like the idea of expanding into different areas of care to help drive down costs, I think owning medical practices and pharmacies can get a bit messy. I see the logic in it, but I also see the possibilities of abuse as well,” Seeking Alpha contributor Geoffrey Seiler wrote in a recently published analysis.
“Walgreens Boots Alliance’s stock has experienced a significant decline since reaching its peak of $87 in 2015, currently at $33. The main factor driving this decline is the drop in margins from 29% in August 2013 to 20% today, attributed to higher costs, lower reimbursements, and increased competition. Despite this, I believe that the market has been too harsh on WBA. Although reimbursement pressures are expected to persist, I think that WBA’s shift in strategy and the recent acquisition will provide some light at the end of the tunnel. Based on my analysis, I value the shares at $40, representing a 21% upside in addition to the +5% dividend,” SA contributor George Atuan said.
Recent News: Earlier this month, California Governor Newsom canceled a $54M contract with WBA over the company’s decision to not sell abortion pills (Mifepristone) in certain states.
WBA stock fell 25% in 2022, while the benchmark S&P 500 index slipped nearly 20% for the year.
